Format
Sort by

Send to:

Choose Destination

Search results

Items: 3

1.

Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers.

Yera-Alos IB, Alonso-Carbonell L, Valenzuela-Silva CM, Tuero-Iglesias AD, Moreira-Martínez M, Marrero-Rodríguez I, López-Mola E, López-Saura PA.

BMC Pharmacol Toxicol. 2013 Sep 3;14:44. doi: 10.1186/2050-6511-14-44.

2.

Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.

García-Vega Y, García-García I, Collazo-Caballero SE, Santely-Pravia EE, Cruz-Ramírez A, Tuero-Iglesias AD, Alfonso-Alvarado C, Cabrera-Placeres M, Castro-Basart N, Duncan-Roberts Y, Carballo-Treto TI, Soto-Matos J, Izquierdo-Toledo Y, Vázquez-Blomquist D, García-Iglesias E, Bello-Rivero I.

BMC Pharmacol Toxicol. 2012 Dec 28;13:20. doi: 10.1186/2050-6511-13-20.

3.

Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor.

Valenzuela-Silva CM, Tuero-Iglesias ÁD, García-Iglesias E, González-Díaz O, Del Río-Martín A, Yera Alos IB, Fernández-Montequín JI, López-Saura PA.

Diabetes Care. 2013 Feb;36(2):210-5. doi: 10.2337/dc12-1323. Epub 2012 Sep 10.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk